


COVID-19 VACCINES:

SAFETY SURVEILLANCE MANUAL




SECOND EDITION



World Health
Organization

COVID-19 VACCINES:

SAFETY SURVEILLANCE MANUAL



SECOND EDITION

COVID-19 vaccines: safety surveillance manual, second edition

ISBN 978-92-4-003278-1 (electronic version)

ISBN 978-92-4-003279-8 (print version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. COVID-19 vaccines: safety surveillance manual, second edition. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see www.who.int/about/who-we-are/publishing-policies/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and Layout: Agence Gardeners

Contents

Acknowledgements	iv
Abbreviations and acronyms	v
Glossary	vii
1. Background	xi
2. Lessons learnt from novel vaccine introduction during pandemic and epidemic emergencies	xii
3. Objectives of this manual	xiii
4. Intended audience	xiv
5. Organization of the manual	xiv
6. Scope of the manual	xiv
6.1. COVID-19 vaccines: description and general safety considerations for implementation	1
6.2. Stakeholders in COVID-19 vaccine safety surveillance	15
6.3. Establishing surveillance systems in countries using COVID-19 vaccines	37
6.4. Monitoring and responding to adverse events following immunization (AEFIs)	57
6.5. Monitoring and responding to adverse events of special interest (AESIs)	81
6.6. Safety data management systems, methods of post-introduction evaluation and assessing performance in countries using COVID-19 vaccines	115
6.7. Engaging with the pharmaceutical industry for COVID-19 vaccine safety surveillance	137
6.8. Regulatory reliance and work-sharing	151
6.9. COVID-19 vaccine safety communication	163
6.10. Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women	215

Acknowledgements

The Pharmacovigilance team in WHO wishes to acknowledge the following experts for their contributions to this manual:

Dure Samin **Akram**, Health Education Literacy Program and Nutrition Resource Center, Pakistan; Narendra Kumar **Arora**, The INCLIN Trust International, India; Aurel Constant **Allabi**, University of Abomey-Calavi, Benin; Steve **Anderson**, Food and Drug Administration (FDA), USA; Maima **Baysah**, Redemption Hospital, Liberia; Cornelia **Betsch**, University of Erfurt, Germany; Steve **Black**, Safety Platform for Emergency vACCines (SPEAC), USA; Noel **Brewer**, UNC Gillings School of Global Public Health, USA; Helen **Byomire Ndagije**, National Drug Authority, Uganda; Laura **Conklin**, Centers for Disease Control and Prevention (CDC), USA; Riadh **Daghfous**, National Pharmacovigilance Center (CNPV), Tunisia; Mimi Delese **Darko**, Food and Drugs Authority, Ghana; Jean-Michel **Dogné**, University of Namur, Belgium; Eve **Dubé**, Institut national de santé publique du Québec, Canada; Jane **Gidudu**, Centers for Disease Control and Prevention (CDC), USA; Gloria **Giraldo**, Public Health Agency of Canada, Canada; Michael **Gold**, University of Adelaide, Australia; Cecilia **Gonzalez**, Ministry of Health, Chile; Abdulrazaq G. **Habib**, Aminu Kano Teaching Hospital, Nigeria; Pradeep **Haldar**, Ministry of Health & Family Welfare, India; Rita **Helfand**, Centers for Disease Control and Prevention (CDC), USA; Kari **Johansen**, European Centre for Disease Prevention and Control (ECDC), Sweden; Emma **Kalk**, Centre for Infectious Disease Epidemiology & Research, University of Cape Town, South Africa; Ambujam **Kapoor**, Indian Council of Medical Research, India; Cindy **Ke Zhou**, Food and Drug Administration (FDA), USA; Li **Keli**, China Center for Disease Control and Prevention, China; Catherine **King**, University of Sydney, Australia; Sonali **Kochhar**, University of Washington, USA; Comfort **Kunak Ogar**, National Agency for Food and Drug Administration and Control, Nigeria; Xavier **Kurz**, European Medicines Agency (EMA), the Netherlands; Barbara **Law**, University of Manitoba, Canada; Julie **Leask**, University of Sydney, Australia; Kristine **Macartney**, University of Sydney, Australia; Ushma **Mehta**, Centre for Infectious Disease Epidemiology & Research, University of Cape Town, South Africa; Afework Assefa **Mitiku**, Paediatrician, International Public Health consultant, Ethiopia; Chris **Morgan**, Monash University, Australia; Sten **Olsson**, Pharmacovigilance Consulting, Sweden; Saad **Omer**, Yale School of Medicine, USA; Maria **Paz Bertoglia Arredondo**, Chilean Epidemiology Society, Chile; Jia **Peiyuan**, Harbin Institute of Technology, China; Monica **Plöen**, Uppsala Monitoring Centre, Sweden; Deepak **Polpakara**, Immunization Technical Support Unit, India; Juan Roldan **Saelzer**, National Agency of Medicines, Chile; Rachida **Soulaymani**, Centre Anti Poison et de Pharmacovigilance WHO Collaborating Center, Morocco; Maryke **Steffens**, University of Sydney, Australia; Miriam **Sturkenboom**, University of Utrecht, the Netherlands; Ming **Su**, Public Health Agency of Canada, Canada; Amina **Tebaa**, Anti-Poison and Pharmacovigilance Centre WHO Collaborating Center, Morocco; Alberto **Tozzi**, Ospedale Pediatrico Bambino Gesù, Italy; Nguyen **Van Cuong**, former EPI Consultant, National Institute of Hygiene and Epidemiology, Viet Nam; Elisabeth **Wilhelm**, Centers for Disease Control and Prevention (CDC), USA; Corinne **Willame**, GSK vaccines, Belgium; Hui-Lee **Wong**, Food and Drug Administration (FDA), USA; Wang **Yali**, National Medical Products Administration, China.

The Pharmacovigilance team wishes to acknowledge all the WHO colleagues for their contributions to this manual.

Abbreviations and acronyms

AACVS	African Advisory Committee on Vaccine Safety
ACE	Angiotensin-converting enzyme
ACT	Access to COVID-19 tools
ADEM	Acute disseminated encephalomyelitis
ADRs	Adverse drug reactions
AEFI	Adverse event following immunization
AESI	Adverse event of special interest
ARDS	Acute respiratory distress syndrome
AVSS	Active vaccine safety surveillance
BMI	Body-mass index
CEM	Cohort event monitoring
CEPI	Coalition for Epidemic Preparedness Innovations
CIOMS	Council for International Organizations of Medical Sciences
COVID-19	Coronavirus disease 2019
DCVMN	Developing Countries Vaccine Manufactures Network
DL	Data linkage
DNA	Deoxyribonucleic acid
EH	e-Health
EPI	Expanded programme on immunization
FIND	Foundation for Innovative New Diagnostics
GACVS	Global Advisory Committee on Vaccine Safety
GBS	Guillain-Barré syndrome
GMP	Good manufacturing practices
GVAP	Global vaccine action plan
HCW	Health care worker
HELLP	Haemolysis, elevated liver enzymes, low platelet count
ICD	International classification of diseases
ICSR	Individual case safety report
IFPMA	International Federation of Pharmaceutical Manufacturers and Associations
ISoP	International Society of Pharmacovigilance
ISRR	Immunization stress-related response
LMIC	Low- and middle-income country
LMP	Last menstrual period

MedDRA	Medical dictionary for regulatory activities
MH	m-Health
MoH	Ministry of Health
mRNA	Messenger RNA
NIP	National Immunization Programme
NITAG	National Immunization Technical Advisory Group
NRA	National regulatory authority
PASS	Post-authorization safety studies
PBRER	Periodic benefit-risk evaluation report
PER	Pregnancy exposure register
PHEIC	Public health emergency of international concern
PIDM	Programme for International Drug Monitoring
PSUR	Periodic safety update report
PV	Pharmacovigilance
QPPV	Qualified person responsible for pharmacovigilance
RITAG	Regional Immunization Technical Advisory Groups
RMP	Risk management plan
RNA	Ribonucleic acid
SAGE	Strategic Advisory Group of Experts (for immunization)
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SKG	Significant knowledge gap
SIA	Supplementary immunization activities
SS	Sentinel surveillance
STI	Sexually transmitted infection
TGA	Therapeutic Goods Administration (Australian Government Department of Health)
UMC	Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Monitoring)
US	Ultrasound

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24173

